返回 
加入收藏
2010－2019年某CRO公司药物临床试验项目盲态审核中方案偏离的相关数据分析
x
请在关注微信后，向客服人员索取文件
| 篇名： | 2010－2019年某CRO公司药物临床试验项目盲态审核中方案偏离的相关数据分析 |
| TITLE： | Data Analysis on Protocol Deviation in Blind Review of Drug Clinical Trials of a CRO Company from 2010 to 2019 |
| 摘要： | 目的：研究方案偏离对药物临床试验结果的影响，为提高药物临床试验的质量管理水平提供参考。方法：收集广州某合同研究组织（CRO）公司2010－2019年药物临床试验的盲态数据审核表，分析方案偏离总体特征“、722公告”（指国家食品药品监督管理总局2015年7月22日发布《关于开展药物临床试验数据自查核查工作的公告》）前后的方案偏离情况以及方案偏离对全分析集（FAS）人群划分的影响，并提出相应建议。结果：最终纳入45个试验项目，涉及454个中心、14304例病例和5562例次方案偏离。最常见的方案偏离类型依次是超窗、违背纳入与排除标准、脱落，分别占方案偏离的36.88％、20.71％、18.43％。不同试验分期和不同药物类型的项目发生方案偏离的程度无统计学意义（P＞0.05），而“722公告”前后不同阶段项目发生方案偏离的程度有显著性差异（P＜0.05）“；722公告”后的超窗、违背纳入与排除标准和服药依从性的偏离发生率有所升高。发生方案偏离的病例有82.07％可以进入FAS，纳入FAS且未进入符合方案集（PPS）的人群占总体偏离人群的53.99％，其中脱落、合并用药偏离分别占19.51％、4.29％，服药依从性偏离的人群均未进入PPS。结论：脱落、违背纳入与排除标准、超窗是造成临床试验方案偏离的主要因素“。722公告”对药物临床试验人员的质量管理意识的提高起到了一定的促进作用。建议应选择恰当的统计方法控制偏倚，从试验设计、人员培训及机构管理建设各方面加强药物临床试验质量管理，减少方案偏离的发生。 |
| ABSTRACT： | OBJECTIVE：To study the effects of protocol deviation on the results of clinical trials ，and to provide reference for rising the quality management of drug clinical trials. METHODS ：Blind data review forms for clinical trials of a contract research organzation （CRO） company in Guangzhou from 2010 to 2019 were collected to analyze general characteristics of protocol deviation，the situation of protocol deviation before and after the “722 announcement”（Announcement on Carrying Out Self-inspection and Verification of Drug Clinical Trial Data issued by CFDA on July 22，2015）as well as the effects of protocol deviation on full analysis set （FAS）population division. The suggestions were put forward. RESULTS ：A total of 45 trials were included，involving 454 centers，14 304 disease cases and 5 562 cases of protocol deviation. The most common types of protocol deviations were over-window ，violation of criteria of the inclusion and exclusion ，and drop-out ，which accounted for 36.88％， 20.71％ and 18.43％ respectively. There was no statistical significance in protocol deviation degree of clinical trials with different stages or drug types （P＞0.05）；there was significant difference in the degree of protocol deviations in clinical trials with different stages before and after the “722 announcement”（P＜0.05）；the incidence of deviations from over-window ，violation of cirteria of the inclusion and exclusion ，and medication compliance had increased after the “722 announcement”；82.07％ of cases with protocol deviations could enter FAS ，and the population who included in FAS but did not enter per protocol set （PPS）accounted for 53.99％ of the total deviation ，of which deviations from drop-out and combined medication accounted for 19.51％ and 4.29％ respectively. All cases with deviation from medication compliance did not enter PPS. CONCLUSIONS ：Drop-out，violation of criteria of the inclusion and exclusion ，and over-window are the main factors that cause clinical trial protocol deviations. The “722 announcement”played a certain role on improving the quality management awareness of the personnel in drug clinical trial. Appropriate statistical methods should be selected to control bias ，and to strengthen the quality management of drug clinical trials and reduce protocol deviations ，by paying attention to trial design， staff training ， institutional management and 85223869。 |
| 期刊： | 2020年第31卷第17期 |
| 作者： | 董玉君，王蓉，余秋钿，程国华 |
| AUTHORS： | DONG Yujun，WANG Rong，YU Qiutian ，CHENG Guohua |
| 关键字： | 方案偏离；药物临床试验；盲态审核；质量管理 |
| KEYWORDS： | Protocol deviation ；Drug clinical trial ；Blind |
| 阅读数： | 356 次 |
| 本月下载数： | 6 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
